Don’t let the high cost of brand single-tablet HIV regimens disrupt your treatment. We help eligible patients access Symtuza (darunavir/cobicistat/emtricitabine/tenofovir alafenamide) for as little as $69.95 per month through the manufacturer’s Patient Assistance Program.
The Symtuza Prescription Assistance Program is a manufacturer-sponsored initiative that provides Symtuza at little or no medication cost to qualifying patients based on income and insurance status. The program is designed for HIV treatment patients who are uninsured or underinsured, as well as Medicare Part D beneficiaries.
Navigating the program on your own means dealing with eligibility verification, HIV provider coordination, prior-authorization documentation, and renewal deadlines.
AffordMyPrescriptions eliminates that burden. For a flat $69.95 per month, our Patient Advocates handle every step of your enrollment, from initial application through ongoing refill coordination and annual re-certification.
| Pharmacy(With Coupon) | PrIce (30-Day)* | You Save W/ Us |
|---|---|---|
| Walgreens | ~$4,400.00 | Save ~$4,330/mo |
| CVS Pharmacy | ~$4,500.00 | Save ~$4,430/mo |
| Walmart | ~$4,100.00 | Save ~$4,030/mo |
| Costco | ~$4,050.00 | Save ~$3,980/mo |
Kroger | ~$4,080.00 | Save ~$4,010/mo |
*Just a heads-up — retail prices are estimates based on public data and vary by pharmacy. AffordMyPrescriptions Advocacy Service bypasses this by using drug manufacturer programs to secure your medication directly at no cost or retail price.
1 Medications
2 Medications
3 Medications
4+ Medications
The Patient Assistance Program is free to apply for and provides Symtuza at no medication cost if approved. Our $69.95/month service covers full advocacy.
Complete a simple eligibility form so our team can determine if you may qualify for medication assistance programs.
Our specialists help gather documentation, complete applications, and coordinate with program providers.
Once approved, you may receive your medication through the assistance program while we help manage ongoing paperwork and renewals.
Many patients try discount cards first. Here’s why the Patient Assistance Program through AffordMyPrescriptions is the better long-term solution for Symtuza:
Still $4,000–$4,500 per month even with the best discount
Eligibility is generally determined by annual household income and insurance status. Most programs follow guidelines that include limits of up to $40,000 for individuals, $60,000 for couples, and $100,000 for larger families. Because requirements vary by program and household, we encourage you to contact AffordMyPrescriptions directly so we can review your specific situation and determine if you qualify for Symtuza assistance.
Not sure if you qualify? Our pre-qualification check is completely free. If we can’t help, you won’t be charged.
Symtuza (DRV/c/FTC/TAF) is a once-daily, single-tablet, four-drug complete HIV-1 regimen combining the protease inhibitor darunavir, the booster cobicistat, and the NRTI backbone of emtricitabine and tenofovir alafenamide.
How Symtuza Works:
Symtuza provides strong combined antiviral pressure by attacking HIV at the protease and reverse transcription stages. Darunavir prevents the virus from maturing into an infectious form, while emtricitabine and TAF block the enzyme responsible for viral DNA synthesis. This regimen utilizes TAF to reduce kidney and bone exposure and relies on darunavir’s high genetic barrier to resistance to prevent the virus from evolving.
Form and use:
This is a complete, single-tablet regimen taken once daily with food, requiring no additional antiretroviral medications. Because it contains cobicistat, a potent booster that interacts with many other drugs, patients must have all their other medications reviewed by a professional before starting. Consistent use with food is essential to maintain the necessary levels of the medication in the body.
Generic availability:
As of 2026, there is no generic version of Symtuza available in the United States. While most current guidelines favor integrase-inhibitor-based regimens like Biktarvy or Dovato for new patients, Symtuza remains a primary option when a protease-inhibitor-based treatment is preferred. Its specific combination of four drugs in one pill is currently only available as a brand-name product.
Warnings:
The medication includes a boxed warning for severe hepatitis B exacerbations if discontinued in co-infected patients, making HBV testing mandatory before starting. It also carries risks of hepatotoxicity, severe skin reactions, and issues for those with sulfa allergies due to the darunavir component. Additional precautions include monitoring for renal impairment, immune reconstitution syndrome, and significant drug interactions caused by the booster.
Symtuza costs approximately $4,000–$4,500 per 30-day supply. Through AffordMyPrescriptions, qualifying patients receive Symtuza at no medication cost — our $69.95 monthly fee covers full advocacy and program management.
Both are once-daily, single-tablet, complete HIV regimens. Symtuza is PI-based (darunavir + cobicistat + FTC + TAF) — high resistance barrier from darunavir, but more drug interactions due to cobicistat. Biktarvy is INSTI-based (bictegravir + FTC + TAF) — also high resistance barrier from bictegravir, fewer drug interactions, smaller tablet. HIV guidelines now generally prefer Biktarvy for new starts. Symtuza is valuable in treatment-experienced patients or those benefiting from a PI-based approach.
Darunavir absorption is increased by food — meaning a low-fat or higher-fat meal both work fine. Skipping food significantly reduces darunavir levels and risks virologic failure. Always take Symtuza with a meal.
Yes — many. Cobicistat is a strong CYP3A inhibitor. This raises levels of many other medications (statins, certain antifungals, antiarrhythmics, anticonvulsants, ergot alkaloids, and more). Some combinations are contraindicated. Always tell every prescriber and pharmacist that you take Symtuza.
Darunavir contains a sulfonamide moiety. Patients with sulfa allergy may have cross-reactivity. Tell your HIV provider about any sulfa allergy. Severe rash, including Stevens-Johnson syndrome, has been reported — any new rash should be evaluated promptly.
Yes. Medicare Part D beneficiaries can typically qualify, especially if you face specialty-tier copays. State ADAP programs may also coordinate with Medicare for HIV-treatment patients.
If denied, we explore alternatives — switching to a different complete single-tablet regimen with its own PAP (Biktarvy, Triumeq, Dovato), or to Prezcobix + separate NRTI backbone, state ADAP, the manufacturer’s copay program for commercially insured patients, or independent foundations. If we cannot find a path, you won’t be charged our service fee.
If you are struggling with the high cost of Symtuza, our team may be able to help you access assistance programs designed to make brand single-tablet HIV regimens affordable. Check your eligibility today.
Start free by filling out a simple online form.
Our specialist will contact you for a quick welcome call.
Our team handles everything, so you can focus on your health.